Skip to main content

Table 1 Summary of completed GLP-1 RA cardiovascular outcome trials for the meta-analysis – primary outcomes and associated hazard ratio in patients with a history of atherosclerotic cardiovascular disease (ASCVD)

From: Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

Study Medication Treatment Number of patients with MACE-3 Hazard ratio (95% CI)
EXSCEL [36] Exenatide Active 722 0.90 (0.82, 1.00)
Placebo 786
Total 1508
LEADER [6] Liraglutide Active 536 0.83 (0.74, 0.93)
Placebo 629
Total 1165
HARMONY [37] Albiglutide Active 338 0.78 (0.68, 0.90)
Placebo 428
Total 766
SUSTAIN-6 [5] Semaglutide Active 98 0.72 (0.55, 0.93)
Placebo 137
Total 235
PIONEER-6 [4] Semaglutide Active 57 0.83 (0.58, 1.17)
Placebo 68
Total 125
REWIND [3] Dulaglutide Active 280 0.87 (0.74,1.02)
Placebo 315
Total 595
  1. CI confidence interval, EXSCEL Exenatide Study of Cardiovascular Event Lowering, GLP-1 RA glucagon-like peptide-1 receptor agonist, LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results, MACE major adverse cardiovascular events (a composite outcome comprising non-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular causes), PIONEER Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer, REWIND Researching Cardiovascular Events With a Weekly Incretin in Diabetes, SUSTAIN Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes